RYTM News and Press, Rhythm Pharmaceuticals Inc. From 07/12/22

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) said its medicine setmelanotide helped reduce Body Mass Index (BMI) in patients with severe obesity and hyperphagia (excessive hunger) in people living with hypothalamic obesity as per interim data from a phase 2 trial. H...

--All evaluable patients (N=11) achieved BMI decrease of more than 5 percent at 16 weeks on setmelanotide therapy-- --17.2 percent mean reduction in BMI at 16 weeks-- --15.8 percent (15.9 kg or 35.1 lb) mean weight reduction achieved at 16 weeks-- --Mean change in ...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) on Wednesday said its Imcivree (setmelanotide) medicine is now available to patients in Germany. RYTM's Imcivree got a marketing authorization from the European Commission last year for the treatment of obesity and the control of hunger caused du...

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced IMCIVREE ® (setmelanotide) is now available...

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European Commission (EC) this week authoriz...

Today we look at penny stocks to buy according to 4 Wall Street analysts. Like most trends in the stock market today, low prices are becoming the norm. This year’s stock market crash has brought plenty of awareness that no company is immune to bearish sentiment and with that has come...

Penny stocks are red hot right now if you know where to look. The overall market has gotten beaten up due to concerns over high inflation and expectations of a recession in 2022. But some have found resolve in day trading or swing trading stocks instead of taking a long-term approach to...

Addex Therapeutics (ADXN) -36% after terminating lead program. ToughBuilt Industries (TBLT) -28%. Advent Technologies (ADN) -13%. Comera Life Sciences (CMRA) -9%. Sidus Space (SIDU) -8%. Aethlon Medical (AEMD) -8%. Rhythm Pharmaceuticals (RYTM) -4% after FDA rejects Rhythm...

Gainers: Cortexyme (CRTX) +7.9%. GoodRx Holdings (GDRX) +5.4%. Concert Pharmaceuticals (CNCE) +4.9%. Roku (ROKU) +4.3%. Mercer International (MERC) +4.3%. Losers: Rhythm Pharmaceuticals (RYTM) -8.5%. Redbox Entertainment (RDBX) -3.6%. KemPharm (KMPH) -3.1%. SS&C Technologies Hol...